Company profile
Jazz Pharmaceuticals PLC logo

Jazz Pharmaceuticals PLC

Pipeline9 assets

  • ZanidatamabHER2 / Bispecific Antibody / Oncology
    Biliary Tract Cancers (BTC)Gastroesophageal Adenocarcinoma (GEA)Colorectal Cancer (CRC)
  • LurbinectedinZepzelca / DNA alkylating / Small Molecule / Oncology
    Small Cell Lung Cancer (SCLC)Ewing Sarcoma
  • DordaviproneModeyso / ClpP agonist / DRD2 antagonist / Small Molecule / Oncology
    H3 K27M-mutant diffuse glioma
  • Daunorubicin and cytarabineJZP351 / Vyxeos / Vyxeos Liposomal / Topoisomerase inhibitor / nucleoside metabolic inhibitor / Liposomal Combination / Oncology
    Myelodysplastic Syndromes (MDS)Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
  • JZP898JZP898 / IFNα2b cytokine pro-drug / Biologic / Oncology
    Solid Tumors
  • JZP3507JZP3507 / ClpP agonist / DRD2 antagonist / Small Molecule / Oncology
    Oncology
  • JZP815JZP815 / pan-RAF / Small Molecule / Oncology
    Solid TumorsHematologic Malignancies
  • CannabidiolEpidyolex / Cannabinoid Receptors / Small Molecule / Neuroscience
    Lennox-Gastaut Syndrome (LGS)Dravet Syndrome (DS)Tuberous Sclerosis Complex (TSC)
  • JZP441JZP441 / Orexin-2 receptor agonist / Small Molecule / Neuroscience
    Narcolepsy Type 1Idiopathic Hypersomnia

Latest news13 items

All news

Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

Expanded safety, subgroup, progression-free survival sensitivity and subsequent therapy analyses further characterize the consistency and durability of outcomes observed with zanidatamab-containing combinations in the first-line setting Additional subgroup analyses to be presented at the 2026 ASCO

Presentation / Abstract • Phase 3ASCO oral presentation Fri, May 29, 2026

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

DUBLIN, May 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: 2026 RBC Global Healthcare Conference on Tuesday, May 19, 2026 at 8:00 a.m.

Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results

– Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) – – Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date of August 25, 2026 – – Xywav ® revenues grew 18% YoY with 425 net patient adds – – Epidiolex ® revenues grew 15% YoY– – Company

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

Prescription Drug User Fee Act (PDUFA) date set for August 25, 2026 For U.S. media and investors only DUBLIN, April 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the

Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)

Rapid oral presentation of PD-L1 subgroup data from HERIZON-GEA-01 evaluating zanidatamab combinations, and additional analyses of tolerability, biomarker response and real-world treatment patterns in HER2+ GEA For U.S. media and investors only DUBLIN, April 21, 2026 /PRNewswire/ -- Jazz

Presentation / Abstract • Phase 3

Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting

Six abstracts, including one oral presentation, underscore Jazz's ongoing commitment to generating real- world evidence addressing rare neurological disorders, including rare and severe forms of epilepsy and sleep disorders For U.S. media and investors only DUBLIN, April 9, 2026 /PRNewswire/

Presentation / Abstract • Phase 4

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

DUBLIN, Feb. 17, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor conferences: TD Cowen 46 th Annual Health Care Conference on Tuesday, March 3, 2026 Fireside chat at 7:30 a.m. PT / 10:30 a.m. ET / 2:30 p.m.

Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer

Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions DUBLIN , Jan. 8, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Thomas Riga as Chief